title: The effect of nesfatin-1 levels on paroxysmal supraventricular tachycardia.
abstract: BACKGROUND
  Nesfatin-1 was originally identified as a neuropeptide of the hypothalamus, which is a key integration area of the brain, where numerous neuropeptides and transmitters are released to participate in the control of essential body functions. In the literature, there are no studies showing the relationship between the nesfatin-1 level and paroxysmal supraventricular tachycardia. We hypothesize that the circulating levels of nesfatin-1 may increase during supraventricular tachycardia, to engage the vagal stimulation to terminate by the inhibition of neuropeptide-Y, and may activate oxytocin and the corticotropin-releasing hormone.
  
  
  METHODS
  This study includes 120 cases (80 patients and 40 controls). Patients with paroxysmal supraventricular tachycardia were compared with the control group with regard to sex, nesfatin-1 level, comorbid diseases, serum renal function values, and patients' vital findings.
  
  
  RESULTS
  The nesfatin-1 levels were significantly higher in the paroxysmal supraventricular tachycardia group than in the control group and positively correlated highly with heart rate (r = 0.634; P < 0.001). The area under the receiver operating characteristic curve was 0.644 for the nesfatin-1 levels (P = 0.0051). The sensitivity and specificity values of the nesfatin-1 levels were 41.2% and 95%, respectively (cutoff value >1743.7 pg/mL).
  
  
  CONCLUSIONS
  At the end of this study, a statistically significant correlation was found between the serum nesfatin-1 level and supraventricular tachycardia. Although multifactorial causes may explain the relationship, we based our hypothesis on the relationship of the antagonistic effects of nesfatin-1 on the neuropeptide-Y and activated oxytocin.
authors.affiliation: Department of Cardiology, Elazig Education and Research Hospital, Elazig, Turkey. ahmetcelik39@hotmail.com
authors.forename: Ahmet
authors.initials: A
authors.lastname: Celik
authors.forename: Mehtap
authors.initials: M
authors.lastname: Gurger
authors.forename: Çagdas
authors.initials: Ç
authors.lastname: Can
authors.forename: Mehmet
authors.initials: M
authors.lastname: Balin
authors.forename: Evrim
authors.initials: E
authors.lastname: Gul
authors.forename: Mehmet Ali
authors.initials: MA
authors.lastname: Kobat
authors.forename: Umut
authors.initials: U
authors.lastname: Gumusay
authors.forename: Mustafa
authors.initials: M
authors.lastname: Sahan
authors.forename: Kazm Burak
authors.initials: KB
authors.lastname: Bursal
authors.forename: Ilyas
authors.initials: I
authors.lastname: Celiker
authors.forename: Suna
authors.initials: S
authors.lastname: Aydin
authors.forename: Suleyman
authors.initials: S
authors.lastname: Aydin
mesh_terms: D000328:Adult; D002135:Calcium-Binding Proteins / Q000097:blood*; D016022:Case-Control Studies; D004268:DNA-Binding Proteins / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D009419:Nerve Tissue Proteins / Q000097:blood*; D000080866:Nucleobindins; D012372:ROC Curve; D013614:Tachycardia, Paroxysmal / Q000097:blood*; D013617:Tachycardia, Supraventricular / Q000097:blood*
chemical_list: D002135:Calcium-Binding Proteins; D004268:DNA-Binding Proteins; C000630650:NUCB2 protein, human; D009419:Nerve Tissue Proteins; D000080866:Nucleobindins